Rockeby Biomed Limited ASX: RBY - Rockeby Biomed Licenses Test For Pre-Eclampsia - Dr Sze-Wee Tan, Chief Executive
Sydney, Jan 18, 2007 (ABN Newswire) - Rockeby Biomed Limited (ASX: RBY) - Rockeby Biomed Licenses Test For Pre-Eclampsia - Dr Sze-Wee Tan, Chief Executive; Boardroomradio is pleased to announce that Rockeby Biomed Limited (ASX: RBY) has published an audio file. The following presentation "Rockeby Biomed Licenses Test For Pre-Eclampsia" is now available as an instant audio download to your computer. You may also transfer this information to your listening device as an IPod podcast.
The BRR service is based on streaming audio sent in compressed form over the internet and displayed as it arrives. You do not have to wait for the whole file to be downloaded before you can hear it, instead the media is sent in a continuous stream and is played immediately as it reaches your computer. Please note that during live broadcasts there can be a delay of approximately 1-2 minutes, depending on traffic through your Internet Service Provider.
Broadcaster: Rockeby Biomed Limited (ASX: RBY)
Broadcast Title: Rockeby Biomed Licenses Test For Pre-Eclampsia
Broadcast Type: Audio stream
View the Audio stream for Rockeby Biomed Limited (ASX: RBY) below.
Rockeby biomed Limited is an ASX-listed (ASX: RBY) biotechnology company engaged primarily in the research, development and marketing of products for the diagnosis and treatment of fungal infections in humans. The company's main market is that of in-vitro diagnostic testing which covers serology tests in hospitals as well as point-of-care products for use by consumers or health professionals operating outside hospitals.
About Boardroomradio
Sydney-based Boardroomradio (BRR) is an Investor Relations multi-media portal delivering audio webcasts to the investment community, including brokers, fund managers, analysts, and private investors.
